(3-fluoro [18f] azetidin-1-YL)(4-(oxazol-5- YL)-6-(trifluoromethyl) indolin-1-YL)methanone and uses thereof
A tracer compound targeting cholesterol 24-hydroxylase in the brain addresses the challenge of imaging and treating neurodegenerative diseases by enabling precise PET imaging and therapeutic intervention.
WO2026142968A1PCT designated stage Publication Date: 2026-07-02EMORY UNIVERSITY
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- EMORY UNIVERSITY
- Filing Date
- 2025-12-19
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
Current technologies lack effective methods for imaging and treating neurodegenerative diseases such as Alzheimer's and Parkinson's by targeting cholesterol 24-hydroxylase activity in the brain.
Method used
Development of a tracer compound (3-fluoro[18F]azetidin-1-yl)(4-(oxazol-5-yl)-6-(trifluoromethyl)indolin-1-yl)methanone, which binds to cholesterol 24-hydroxylase, allowing PET imaging and potential therapeutic intervention.
Benefits of technology
Enables accurate imaging and treatment of neurodegenerative diseases by highlighting cholesterol 24-hydroxylase activity and providing a potential therapeutic agent for these conditions.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025060690_02072026_PF_FP_ABST
Abstract
Disclosed herein is a tracer compound (3-fluoro[18F]azetidin-1-yl)(4-(oxazol-5-yl)-6-(trifluoromethyl)indolin-1-yl)methanone, derivative, or salt thereof and uses as an imaging agent. In certain embodiments, this disclosure relates to precursor compounds such as 1-(4-(oxazol-5-yl)-6-(trifluoromethyl)indoline-1-carbonyl)azetidin-3-yl 4-nitrobenzenesulfonate, derivative, or salt thereof and kits comprising the same.
Need to check novelty before this filing date? Find Prior Art